Mereo BioPharma (MREO) Common Equity (2017 - 2026)

Mereo BioPharma (MREO) has 7 years of Common Equity data on file, last reported at $34.1 million in Q1 2026.

• Common Equity for Q1 2026 came in at $34.1 million, down 43.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.1 million (down 43.32% YoY), and the FY2025 annual result was $40.9 million, down 32.89% from the prior year.
• Common Equity declined to $34.1 million in Q1 2026 per MREO's latest filing, from $40.9 million in the prior quarter.
• Over five years, Common Equity peaked at $78.6 million in Q2 2024 and troughed at -$72.5 million in Q3 2024.
• A 5-year average of $42.6 million and a median of $50.1 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 232.59% in 2024, then surged 164.24% in 2025.
• A 5-year view of Common Equity shows it stood at $51.4 million in 2022, then decreased by 1.68% to $50.5 million in 2023, then climbed by 20.64% to $61.0 million in 2024, then plunged by 32.89% to $40.9 million in 2025, then dropped by 16.77% to $34.1 million in 2026.
• Business Quant data shows MREO's Common Equity at $34.1 million in Q1 2026, $40.9 million in Q4 2025, and $46.6 million in Q3 2025.